Trial Profile
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Mar 2023
Price :
$35
*
At a glance
- Drugs Sitravatinib (Primary) ; Tislelizumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Proof of concept
- Sponsors BeiGene
- 10 Jan 2023 Status changed from active, no longer recruiting to completed.
- 09 Aug 2022 Results (n=24; Between May 12, 2020 and February 10, 2021; data cut-off November 8, 2021) assessing safety, tolerability, and antitumor activity of sitravatinib and tislelizumab in patients with programmed death-ligand 1 positive, squamous non-small cell lung cancer, presented at the 2022 World Conference on Lung Cancer.
- 09 Aug 2022 Results (n=22) assessing results from patients with programmed death-ligand 1 positive, non-squamous non-small cell lung cancer , presented at the 2022 World Conference on Lung Cancer.